Entospletinib (GS-9973)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 01:25, 21 April 2015 by Jwarner (talk | contribs) (Created page with "=Mechanism of action= Spleen tyrosine kinase (SYK) inhibitor =Preliminary data= ==CLL== # Sharman...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Mechanism of action

Spleen tyrosine kinase (SYK) inhibitor

Preliminary data

CLL

  1. Sharman J, Hawkins M, Kolibaba K, Boxer M, Klein L, Wu M, Hu J, Abella S, Yasenchak C. An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2015 Apr 9;125(15):2336-43. Epub 2015 Feb 18. link to original article PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Entospletinib_(GS-9973)&oldid=7815"